From Bench to Bedside: Translating Cellular Rejuvenation Therapies into Clinical Applications DOI Creative Commons
Timur Saliev, Prim B. Singh

Cells, Journal Year: 2024, Volume and Issue: 13(24), P. 2052 - 2052

Published: Dec. 12, 2024

Cellular rejuvenation therapies represent a transformative frontier in addressing age-related decline and extending human health span. By targeting fundamental hallmarks of aging—such as genomic instability, epigenetic alterations, mitochondrial dysfunction, cellular senescence—these aim to restore youthful functionality cells tissues, offering new hope for treating degenerative diseases. Recent advancements have showcased range strategies, including reprogramming, senolytic interventions, restoration, stem cell-based approaches, gene-editing technologies like CRISPR. Each modality has demonstrated substantial potential preclinical models is now being cautiously explored early-stage clinical trials. However, translating these from the laboratory practice presents unique challenges: safety concerns, delivery precision, complex regulatory requirements, ethical considerations, high costs impede widespread adoption. This review examines current landscape rejuvenation, highlighting key advancements, risks, strategies needed overcome hurdles.

Language: Английский

From Bench to Bedside: Translating Cellular Rejuvenation Therapies into Clinical Applications DOI Creative Commons
Timur Saliev, Prim B. Singh

Cells, Journal Year: 2024, Volume and Issue: 13(24), P. 2052 - 2052

Published: Dec. 12, 2024

Cellular rejuvenation therapies represent a transformative frontier in addressing age-related decline and extending human health span. By targeting fundamental hallmarks of aging—such as genomic instability, epigenetic alterations, mitochondrial dysfunction, cellular senescence—these aim to restore youthful functionality cells tissues, offering new hope for treating degenerative diseases. Recent advancements have showcased range strategies, including reprogramming, senolytic interventions, restoration, stem cell-based approaches, gene-editing technologies like CRISPR. Each modality has demonstrated substantial potential preclinical models is now being cautiously explored early-stage clinical trials. However, translating these from the laboratory practice presents unique challenges: safety concerns, delivery precision, complex regulatory requirements, ethical considerations, high costs impede widespread adoption. This review examines current landscape rejuvenation, highlighting key advancements, risks, strategies needed overcome hurdles.

Language: Английский

Citations

1